Massachusetts Hospitals Sue Eli Lilly Over 340B Data Demands

Five Massachusetts health systems—Massachusetts General Hospital, Brigham and Women’s Hospital, Salem Hospital, UMass Memorial Medical Center, and UMass Memorial Health—filed a federal suit in Boston alleging that Eli Lilly violated the federal 340B drug-pricing program. The hospitals contend Lilly’s demand for privacy-protected patient-level data, routed through a private-equity-owned platform, threatens federal privacy rules and amounts to corporate extortion. They argue the request jeopardizes the “tens of millions of dollars” in drug-price discounts that keep community health services operating.

Boston Globe

Created by Congress, the 340B program obligates drug manufacturers to sell outpatient medicines at reduced prices to eligible health-care entities that serve uninsured and low-income patients. Discounts are intended to fund free care, mobile health vans, school dental programs, addiction-treatment teams, and other community services. Hospitals in the lawsuit say the program’s savings fund free care at 28 public schools, mobile addiction-treatment units, and medical-respite beds for unhoused individuals.

Boston Globe

Eli Lilly, the world’s largest pharmaceutical company and the first to reach a trillion-dollar market capitalization, issued a statement asserting that Congress designed 340B “to help vulnerable patients.” The company claims the hospitals’ refusal to share routine claims data—information it says insurers already receive—hinders efforts to prevent “double-dipping” of discounts across programs such as Medicaid. Lilly also noted its Indianapolis headquarters and a $700 million Boston research center as evidence of its commitment to the U.S. health system.

Boston Globe

Hospital representatives counter that Lilly’s new data-collection platform is a “commercially valuable” extraction of information without compensation, and that the demand violates patient-privacy law. They emphasize that the discounts sustain essential community services, from mobile cardiovascular screenings to fresh-food markets.

Boston Globe

• “Our patients trust us with their most personal information and protecting that trust is part of caring for them,” — Dr. Patrick Gordan, Salem Hospital’s associate chief medical officer

Boston Globe

If the courts side with the hospitals, pharmaceutical firms may be limited in demanding detailed patient data from 340B participants, preserving privacy protections and the flow of discounted drugs to underserved populations. Conversely, a ruling favoring Lilly could set a precedent for broader data-sharing requirements, potentially reshaping how drug-price discounts are monitored and how hospitals fund community health initiatives.

Boston Globe